This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The confident answers on tracking a shortage and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Where a shortage forces a gap, the pharmacokinetics mean a missed week is a perturbation rather than a reset, which is worth knowing.
Switching presentation or strength during a shortage is a prescribing decision rather than a substitution anybody should improvise.
This follows post #64 rather than contradicting it.
Shortage-driven price movement is real and is a separate question from availability.
I am aware this is the third time this month I have made this point.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
Post #67 and I disagree about the size of the effect, not about the direction.
Pharmacy-level availability varies enormously during a shortage, so two honest accounts from the same city can be opposite.
The rule of thumb is fine; the edge cases are where it earns its keep.
Taking post #67 at face value and following it one step further.
Regional differences during a shortage are large, and a supply position in one country says nothing about another.
I would treat the number as indicative rather than as a measurement.
Fair, and the limits you put on it are the part I will remember.
I had written a reply contradicting post #68 and deleted it. Here is what survived.
Checked the tracking a shortage claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
Planning around a known shortage window is easier than reacting to one, and the notices give advance warning more often than people expect.
Reading it again, the caveat matters more than the finding.
Post #74 is the version of this I will quote in future. One addition.
Tracking a shortage came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Where I part company with post #72, and it is a narrow parting.
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).
Genuinely open to being wrong about this one.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Pharmacy-level availability varies enormously during a shortage, so two honest accounts from the same city can be opposite.
A guess, clearly labelled as one.
Post #81 is the version of this I will quote in future. One addition.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
Shortage status determines what compounding is permitted in some jurisdictions, which links two questions that otherwise seem unrelated.
Post #85 put the caveat in the right place and I want to underline it.
Reading this tracking a shortage thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
Building on post #85 rather than restating it.
The number people quote for tracking a shortage is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.
Where an alternative within the class is available, the comparison is a clinical one and the doses are not equivalent.